







UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/600,392	09/08/2000	Charles W. Ford	6137.P US	4850
75	12/26/2001			
Ann M Mueting Mueting Raasch & Gebhardt PO Box 581415 Minneapolis, MN 55458-1415			EXAMINER	
			LEFFERS JR, GERALD G	
			ART UNIT	PAPER NUMBER
			1636	0
			DATE MAILED: 12/26/2001	X

Please find below and/or attached an Office communication concerning this application or proceeding.

		Applicati	on No.	Applicant(s)			
Office Action Summary		09/600,3	92	FORD ET AL.			
		Examin		Art Unit			
		Gerald G	Leffers Jr.	1636			
The MAILING DATE of this communication appears on the cover she t with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status							
1)							
2a) <u></u>	<u> </u>						
3)	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4) Claim(s) 1-77 is/are pending in the application.							
•	4a) Of the above claim(s) is/are withdrawn from consideration.						
5)	5) Claim(s) is/are allowed.						
6)	6) Claim(s) is/are rejected.						
7)	Claim(s) is/are objected to.						
8) Claim(s) 1-77 are subject to restriction and/or election requirement.							
Application Papers							
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some * c) None of:							
	1. Certified copies of the priority docur			. No			
2. Certified copies of the priority documents have been received in Application No							
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
2) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948 nation Disclosure Statement(s) (PTO-1449) Paper No			y (PTO-413) Paper No(s) Patent Application (PTO-152)			

Application/Control Number: 09/600,392

Art Unit: 1636

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions that are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-20 and 77 drawn to a process for characterization of a microbial gene wherein the gene is controllably expressed in a microbial cell in a mammal.

Group II, claim(s) 21-32, 34-49, 51-75, drawn to nucleic acids for integration of a polynucleotide sequence comprising a tetracycline-inducible element into a target DNA molecule (e.g. the *ef-tu* gene), and vectors/host cells comprising said nucleic acids.

Group III, claim(s) 21-32, 34-49, 51-75, drawn to nucleic acids for integration of a polynucleotide sequence comprising a tetracycline-controllable element into a target DNA molecule (e.g. the *femA* gene), and vectors/host cells comprising said nucleic acids.

Group IV, claim(s) 21-31, 33-48, 50-75 drawn to drawn to nucleic acids for integration of a polynucleotide sequence comprising a tetracycline-controllable element into a target DNA molecule (e.g. the *lgt* gene), and vectors/host cells comprising said nucleic acids.

Group V, claim(s) 76, drawn to a method for controlled expression of a gene in a microbial cell grown in culture.

The inventions listed as Groups I-V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the special technical feature of Group I is the use of a tetracycline-controllable element to express a desired gene in a microbial organism in a host mammal. This special technical feature is not present in, or required for, the inventions of the

Art Unit: 1636

other groups. Groups II-IV have a unique special technical feature dependent upon nucleic acid sequences having unique characteristics (e.g. ef-tu, femA or lgt target sequences). Group V has a special technical feature, expression of a desired gene in a cell grown in culture, that is not present in, or required for, the inventions of the other groups.

Conclusion

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gerald G Leffers Jr. whose telephone number is (703) 308-6232. The examiner can normally be reached on 9:30am-6:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, George Elliot can be reached on (703) 308-4003. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-7939 for regular communications and (703) 305-7939 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

> Gerald G Leffers Jr. Examiner Art Unit 1636

December 21, 2001

PRIMARY EXAMINER